The therapy, dubbed OST-HER2, uses a HER2-bioengineered form of the bacteria Listeria monocytogenes to trigger an immune ...

GE HealthCare is launching a new imaging research collaboration with the University of California, San Francisco, aimed at ...

The FDA is elevating a recall from Philips related to one of its wearable outpatient heart monitors, used to help detect ...

A month after halting dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial hypertension ...

Yesterday, spots of pink could be spotted on the streets of San Francisco, and it wasn’t a coincidence. Members of the ...

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...

Neumora Therapeutics’ phase 3 fail was worse than analysts feared. | Neumora Therapeutics’ phase 3 fail was worse than ...

Daiichi Sankyo is turning to the German city of Heidelberg for help developing antibodies. The Japanese pharma giant is ...

Welcome to Day 2 of the J.P. Morgan Healthcare Conference 2025 in San Francisco. | Welcome to Day 2 of the J.P. Morgan ...

With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now ...

N-Power Medicine, a tech firm with a clinical trial platform for capturing real-world patient data, has acquired precision ...

Sling Therapeutics’ oral challenger to Amgen’s intravenous Tepezza has hit the mark in a phase 2b/3 thyroid eye disease (TED) ...